首页 > 最新文献

Pharmaceutical patent analyst最新文献

英文 中文
Proposed supplementary protection certificate legislation for medicinal products. 拟议的医药产品补充保护证书立法。
IF 1.3 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-11-01 Epub Date: 2024-01-10 DOI: 10.4155/ppa-2023-0031
Olivia J Creemer, Stephen Garner
{"title":"Proposed supplementary protection certificate legislation for medicinal products.","authors":"Olivia J Creemer, Stephen Garner","doi":"10.4155/ppa-2023-0031","DOIUrl":"10.4155/ppa-2023-0031","url":null,"abstract":"","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139404018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patent Highlights April-May 2023. 2023 年 4 月至 5 月的专利亮点。
IF 1.3 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-11-01 Epub Date: 2024-01-10 DOI: 10.4155/ppa-2023-0028
Hermann Am Mucke

A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.

与制药和医疗研发相关的专利文献中值得关注的最新进展快照。
{"title":"Patent Highlights April-May 2023.","authors":"Hermann Am Mucke","doi":"10.4155/ppa-2023-0028","DOIUrl":"10.4155/ppa-2023-0028","url":null,"abstract":"<p><p>A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139404016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Progression and expansion of quinoline as bioactive moiety: a patent review. 作为生物活性分子的喹啉的进步与发展:专利回顾。
IF 1.3 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-11-01 Epub Date: 2024-01-31 DOI: 10.4155/ppa-2023-0025
Yash Chauhan, Kumari Neha, Sharad Wakode, Mohd Shahfaiz, Ramesh B Bodla, Kalicharan Sharma

Quinoline inhibitors are appealing medicinal products for a range of illnesses and problems. It is bicyclic heterocyclic scaffold has been intensively employed in pharmacological research and is well known for its wide range of biological purposes. Biological activities exhibited by quinoline derivatives, such as anti-inflammatory properties, antioxidant, antimicrobial, anti-tubercular, antidiabetic, anti-malarial and others are covered in detail in this review. The IC50 of patented inhibitors might range from nm to μM range, based on the experiments used. It presents an outline of patents file between 2002 and 2023 concerning to biological activities by quinoline derivatives. As a result, it is critical to develop additional chemical quinoline core alterations for novel chemical compounds and enhanced pharmacological impacts.

喹啉抑制剂是治疗一系列疾病和问题的极具吸引力的药物产品。喹啉是一种双环杂环支架,已被广泛应用于药理学研究,并以其广泛的生物学用途而著称。本综述将详细介绍喹啉衍生物所表现出的生物活性,如抗炎性、抗氧化性、抗菌性、抗结核性、抗糖尿病性、抗疟疾性等。根据所用实验,专利抑制剂的 IC50 值可能在 nm 到 μM 之间。本综述概述了 2002 年至 2023 年期间有关喹啉衍生物生物活性的专利申请。因此,开发更多的喹啉核心化学变化以获得新型化合物并增强药理作用至关重要。
{"title":"Progression and expansion of quinoline as bioactive moiety: a patent review.","authors":"Yash Chauhan, Kumari Neha, Sharad Wakode, Mohd Shahfaiz, Ramesh B Bodla, Kalicharan Sharma","doi":"10.4155/ppa-2023-0025","DOIUrl":"10.4155/ppa-2023-0025","url":null,"abstract":"<p><p>Quinoline inhibitors are appealing medicinal products for a range of illnesses and problems. It is bicyclic heterocyclic scaffold has been intensively employed in pharmacological research and is well known for its wide range of biological purposes. Biological activities exhibited by quinoline derivatives, such as anti-inflammatory properties, antioxidant, antimicrobial, anti-tubercular, antidiabetic, anti-malarial and others are covered in detail in this review. The IC<sub>50</sub> of patented inhibitors might range from nm to μM range, based on the experiments used. It presents an outline of patents file between 2002 and 2023 concerning to biological activities by quinoline derivatives. As a result, it is critical to develop additional chemical quinoline core alterations for novel chemical compounds and enhanced pharmacological impacts.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139642691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patenting trends by Mexican pharmaceutical companies. 墨西哥制药公司的专利申请趋势。
IF 1.3 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-11-01 Epub Date: 2024-01-10 DOI: 10.4155/ppa-2023-0029
Luis Villafaña-Diaz, Juan C Perez-Garcia, Diana Barron-Villaverde, Martin Perez-Santos

Aim: the activity of patent claims by Mexican pharmaceutical companies is unknown. Objective: analyse the trend in patents of Mexican pharmaceutical companies. Method: a search for patents was carried out in the patent database of the Mexican Institute of Industrial Property, using the list of Mexican pharmaceutical companies belonging to the Mexican Association of Pharmaceutical Research Industries, and the codes A61K, A61P and C07 of the International Patent Classification. Results: the leading companies in patent applications were Liomont, Senosiain and RIMSA; however, Mexican pharmaceutical companies claim very few patents, only 266 patent applications in the period 2000-2020, with a technological factor with a value of zero, and a commercial factor of little value. Conclusion: Mexican pharmaceutical companies lack a robust patent system, without growth, and with a low percentage of patents with high commercial value.

目的:墨西哥制药公司的专利申请活动尚不为人知。目的:分析墨西哥制药公司的专利趋势。方法:在墨西哥工业产权局的专利数据库中,利用墨西哥制药研究工业协会所属的墨西哥制药公司名单和国际专利分类代码 A61K、A61P 和 C07 进行专利检索。结果:专利申请量最大的公司是利奥蒙德、塞诺西亚因和 RIMSA;然而,墨西哥制药公司申请的专利很少,2000-2020 年间仅有 266 项专利申请,技术因素值为零,商业因素值很小。结论:墨西哥制药公司缺乏健全的专利制度,没有增长,商业价值高的专利比例低。
{"title":"Patenting trends by Mexican pharmaceutical companies.","authors":"Luis Villafaña-Diaz, Juan C Perez-Garcia, Diana Barron-Villaverde, Martin Perez-Santos","doi":"10.4155/ppa-2023-0029","DOIUrl":"10.4155/ppa-2023-0029","url":null,"abstract":"<p><p><b>Aim:</b> the activity of patent claims by Mexican pharmaceutical companies is unknown. <b>Objective:</b> analyse the trend in patents of Mexican pharmaceutical companies. <b>Method:</b> a search for patents was carried out in the patent database of the Mexican Institute of Industrial Property, using the list of Mexican pharmaceutical companies belonging to the Mexican Association of Pharmaceutical Research Industries, and the codes A61K, A61P and C07 of the International Patent Classification. <b>Results:</b> the leading companies in patent applications were Liomont, Senosiain and RIMSA; however, Mexican pharmaceutical companies claim very few patents, only 266 patent applications in the period 2000-2020, with a technological factor with a value of zero, and a commercial factor of little value. <b>Conclusion:</b> Mexican pharmaceutical companies lack a robust patent system, without growth, and with a low percentage of patents with high commercial value.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139404017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lipid-based mesoporous silica nanoparticles: a paradigm shift in management of pancreatic cancer. 基于脂质的介孔二氧化硅纳米粒子:胰腺癌治疗模式的转变。
IF 1.3 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-11-01 Epub Date: 2024-01-12 DOI: 10.4155/ppa-2023-0024
Kiran Kumar Bellapu, Ramesh Joga, Bharthi R Kannan, Sravani Yerram, Priya Varpe, Tejaswini Mergu, Pavan Y Vasu, Saurabh Srivastava, Sandeep Kumar

Pancreatic adenocarcinoma, a devastating disease, has the worst cancer prognosis in humans. It often develops resistance to common chemotherapy medications, such as gemcitabine, taxol and 5-fluorouracil. The dense stroma limits therapeutic efficacy in treating this disease. Low or limited drug loading capacity is another problem with current chemotherapeutic agents. There is a need to develop novel approaches to overcome these issues. Hence, an innovative approach has been proposed to co-deliver both hydrophilic (Gemcitabine) and hydrophobic (Paclitaxel) drugs in a single carrier using lipid bilayer-mesoporous silica nanoparticles (LB-MSNP). MSNPs offer effective drug delivery due to their superior bioavailability and physicochemical properties. Further, in order to achieve clinical translation and regulatory approval, toxicity and biodegradability of MSNPs must be resolved.

胰腺腺癌是一种毁灭性疾病,是人类预后最差的癌症。它常常对吉西他滨、紫杉醇和 5-氟尿嘧啶等常见化疗药物产生抗药性。致密的基质限制了治疗这种疾病的疗效。药物负荷能力低或有限是目前化疗药物的另一个问题。需要开发新的方法来克服这些问题。因此,有人提出了一种创新方法,利用脂质双分子层-介孔二氧化硅纳米颗粒(LB-MSNP)在单一载体中同时递送亲水性药物(吉西他滨)和疏水性药物(紫杉醇)。MSNP 具有优异的生物利用度和理化特性,可提供有效的药物输送。此外,为了实现临床转化和监管审批,必须解决 MSNP 的毒性和生物降解性问题。
{"title":"Lipid-based mesoporous silica nanoparticles: a paradigm shift in management of pancreatic cancer.","authors":"Kiran Kumar Bellapu, Ramesh Joga, Bharthi R Kannan, Sravani Yerram, Priya Varpe, Tejaswini Mergu, Pavan Y Vasu, Saurabh Srivastava, Sandeep Kumar","doi":"10.4155/ppa-2023-0024","DOIUrl":"10.4155/ppa-2023-0024","url":null,"abstract":"<p><p>Pancreatic adenocarcinoma, a devastating disease, has the worst cancer prognosis in humans. It often develops resistance to common chemotherapy medications, such as gemcitabine, taxol and 5-fluorouracil. The dense stroma limits therapeutic efficacy in treating this disease. Low or limited drug loading capacity is another problem with current chemotherapeutic agents. There is a need to develop novel approaches to overcome these issues. Hence, an innovative approach has been proposed to co-deliver both hydrophilic (Gemcitabine) and hydrophobic (Paclitaxel) drugs in a single carrier using lipid bilayer-mesoporous silica nanoparticles (LB-MSNP). MSNPs offer effective drug delivery due to their superior bioavailability and physicochemical properties. Further, in order to achieve clinical translation and regulatory approval, toxicity and biodegradability of MSNPs must be resolved.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139425271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prominence of bioresponsive DNA nanococoons in tackling post-surgery cancer recurrence. 生物反应性DNA纳米茧在治疗术后癌症复发中的突出作用。
IF 1.3 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-09-01 Epub Date: 2023-11-20 DOI: 10.4155/ppa-2023-0013
Sravani Yerram, Ramesh Joga, Pooja Shende, Priya Varpe, Kiran Kumar Bellapu, Sandeep Kumar

Post-surgery cancer recurrence is one of the reasons for increased cancer cases. The effective usage of the enhanced permeability and retention effect of a nanocarrier infused with the bioresponsive release mechanism of checkpoint inhibitors (aPD1 and aCTLA4) can become a boon to mankind. DNA nanococoons (DNCs) comprising cytosine-phosphorothioate-guanine oligodeoxynucleotides (CpG-ODNs) with potent immunostimulatory effects can significantly enhance anti-cancer activity. Triglycerylmonostearate (TGMS) with enzymatic cleavage potential at the wound sites of tumor resection, upon caging with restriction enzyme (HhaI) followed by attaching to DNCs, makes the immunotherapy bioresponsive. Hhal-TGMS-DNCs-aPD1 triggered by the inflammation at the wound site undergoes enzymatic cleavage, releases the restriction enzyme, converts DNCs to CpG ODNs sequentially and with sustained aPD1 release exerts an appreciable anti-cancer effect.

术后癌症复发是癌症病例增加的原因之一。有效利用注入检查点抑制剂(aPD1和aCTLA4)生物反应性释放机制的纳米载体的增强渗透性和滞留效应,可以成为人类的福音。含有胞嘧啶-硫代磷酸酯-鸟嘌呤寡聚脱氧核苷酸(CpG-ODNs)的DNA纳米cocoons (dnc)具有较强的免疫刺激作用,可以显著增强抗癌活性。甘油三酯单硬脂酸酯(TGMS)在肿瘤切除的伤口部位具有酶切电位,在用限制性内切酶(HhaI)笼化后附着在dnc上,使免疫治疗具有生物反应性。伤口部位炎症触发的hhal - tgms - dnc -aPD1经过酶裂解,释放限制性内切酶,将dnc依次转化为CpG ODNs,并持续释放aPD1,具有明显的抗癌作用。
{"title":"Prominence of bioresponsive DNA nanococoons in tackling post-surgery cancer recurrence.","authors":"Sravani Yerram, Ramesh Joga, Pooja Shende, Priya Varpe, Kiran Kumar Bellapu, Sandeep Kumar","doi":"10.4155/ppa-2023-0013","DOIUrl":"10.4155/ppa-2023-0013","url":null,"abstract":"<p><p>Post-surgery cancer recurrence is one of the reasons for increased cancer cases. The effective usage of the enhanced permeability and retention effect of a nanocarrier infused with the bioresponsive release mechanism of checkpoint inhibitors (aPD1 and aCTLA4) can become a boon to mankind. DNA nanococoons (DNCs) comprising cytosine-phosphorothioate-guanine oligodeoxynucleotides (CpG-ODNs) with potent immunostimulatory effects can significantly enhance anti-cancer activity. Triglycerylmonostearate (TGMS) with enzymatic cleavage potential at the wound sites of tumor resection, upon caging with restriction enzyme (HhaI) followed by attaching to DNCs, makes the immunotherapy bioresponsive. Hhal-TGMS-DNCs-aPD1 triggered by the inflammation at the wound site undergoes enzymatic cleavage, releases the restriction enzyme, converts DNCs to CpG ODNs sequentially and with sustained aPD1 release exerts an appreciable anti-cancer effect.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138047733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Steroid sulfatase inhibitors and sulfated C19 steroids for proteotoxicity-related diseases: a patent spotlight. 类固醇磺化酶抑制剂和硫酸C19类固醇治疗蛋白质毒性相关疾病:专利焦点
IF 1.8 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2023-09-01 Epub Date: 2023-11-20 DOI: 10.4155/ppa-2023-0010
Rami A Al-Horani

Aging and proteotoxicity go hand in hand. Inhibiting proteotoxicity has been proposed to extend lifespan. This invention describes a new strategy to limit proteotoxicity and to extend the lifespan. Loss of function of sul-2, the Caenorhabditis elegans steroid sulfatase, elevates the pool of sulfated steroid hormones, increases longevity and ameliorates protein aggregation diseases. The present invention provides a group of molecules for use in the prevention of aging-associated proteotoxicity caused by protein aggregation diseases and/or to increase the lifespan of a eukaryotic organism. These molecules are either steroid sulfatase inhibitors or sulfated C19 steroids, both of which reproduce the phenotype of sul-2 mutants. One particular representative example is STX-64. Potential applications of the claims have been demonstrated in animal models of Parkinson's disease, Huntington's disease and Alzheimer's disease.

衰老和蛋白质毒性是密切相关的。抑制蛋白质毒性被认为可以延长寿命。本发明描述了一种限制蛋白质毒性和延长寿命的新策略。秀丽隐杆线虫类固醇硫酸酯酶sul2功能的丧失,增加了硫酸类固醇激素的数量,延长了寿命,改善了蛋白质聚集性疾病。本发明提供了一组分子,用于预防由蛋白质聚集疾病引起的与衰老相关的蛋白质毒性和/或增加真核生物的寿命。这些分子要么是类固醇硫酸酯酶抑制剂,要么是硫酸C19类固醇,两者都能产生硫-2突变体的表型。一个典型的例子是STX-64。这些说法的潜在应用已经在帕金森病、亨廷顿病和阿尔茨海默病的动物模型中得到证实。
{"title":"Steroid sulfatase inhibitors and sulfated C19 steroids for proteotoxicity-related diseases: a patent spotlight.","authors":"Rami A Al-Horani","doi":"10.4155/ppa-2023-0010","DOIUrl":"10.4155/ppa-2023-0010","url":null,"abstract":"<p><p>Aging and proteotoxicity go hand in hand. Inhibiting proteotoxicity has been proposed to extend lifespan. This invention describes a new strategy to limit proteotoxicity and to extend the lifespan. Loss of function of <i>sul-2</i>, the <i>Caenorhabditis elegans</i> steroid sulfatase, elevates the pool of sulfated steroid hormones, increases longevity and ameliorates protein aggregation diseases. The present invention provides a group of molecules for use in the prevention of aging-associated proteotoxicity caused by protein aggregation diseases and/or to increase the lifespan of a eukaryotic organism. These molecules are either steroid sulfatase inhibitors or sulfated C19 steroids, both of which reproduce the phenotype of <i>sul-2</i> mutants. One particular representative example is STX-64. Potential applications of the claims have been demonstrated in animal models of Parkinson's disease, Huntington's disease and Alzheimer's disease.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":null,"pages":null},"PeriodicalIF":1.8,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10782412/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138047734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patent highlights February-March 2023. 专利亮点2023年2月至3月。
IF 1.3 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-09-01 Epub Date: 2023-11-20 DOI: 10.4155/ppa-2023-0023
Hermann Am Mucke

A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.

与制药和医学研究与开发相关的专利文献中值得注意的最新发展概况。
{"title":"Patent highlights February-March 2023.","authors":"Hermann Am Mucke","doi":"10.4155/ppa-2023-0023","DOIUrl":"10.4155/ppa-2023-0023","url":null,"abstract":"<p><p>A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138047732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recent patents in the treatment and prevention of leishmaniasis. 治疗和预防利什曼病的最新专利。
IF 1.3 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-09-01 Epub Date: 2023-12-08 DOI: 10.4155/ppa-2023-0022
Sukhbir K Shahid

Leishmaniasis, a neglected tropical disease, is caused by protozoal parasites of the genus Leishmania. Clinical manifestations vary from asymptomatic to lethal grade depending on the type of the disease. The currently available antileishmanial drugs suffer from considerable limitations. There is a dire need for better and safer drugs and/or vaccines to eradicate this disease. There are enormous developments ongoing in this field. Newer combinations of existing drugs and newer drugs targeting these intracellular parasites as well as their vectors are being tried to control the disease. Attempts to develop vaccines to enhance the immunity of the patient have shown some promise. This article is a peep into the recent patent developments in this field.

利什曼病是一种被忽视的热带疾病,由利什曼属原生动物寄生虫引起。临床表现因疾病类型而异,从无症状到致命程度不等。目前可用的抗利什曼病药物存在相当大的局限性。我们迫切需要更好、更安全的药物和/或疫苗来根除这种疾病。这一领域正在取得巨大进展。人们正在尝试将现有药物和针对这些细胞内寄生虫及其载体的新药组合起来,以控制这种疾病。开发疫苗以增强患者免疫力的尝试也已初见成效。本文将对这一领域的最新专利进展进行介绍。
{"title":"Recent patents in the treatment and prevention of leishmaniasis.","authors":"Sukhbir K Shahid","doi":"10.4155/ppa-2023-0022","DOIUrl":"https://doi.org/10.4155/ppa-2023-0022","url":null,"abstract":"<p><p>Leishmaniasis, a neglected tropical disease, is caused by protozoal parasites of the genus <i>Leishmania</i>. Clinical manifestations vary from asymptomatic to lethal grade depending on the type of the disease. The currently available antileishmanial drugs suffer from considerable limitations. There is a dire need for better and safer drugs and/or vaccines to eradicate this disease. There are enormous developments ongoing in this field. Newer combinations of existing drugs and newer drugs targeting these intracellular parasites as well as their vectors are being tried to control the disease. Attempts to develop vaccines to enhance the immunity of the patient have shown some promise. This article is a peep into the recent patent developments in this field.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138807301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Drug repurposing of rimantadine for treatment of cancer. 金刚乙胺治疗癌症的药物再利用。
IF 1.3 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2023-09-01 Epub Date: 2023-11-20 DOI: 10.4155/ppa-2023-0019
Nemesio Villa-Ruano, Vianey Marin-Cevada, Gabriela Sanchez-Esgua, Luis Villafaña-Diaz, Martin Perez-Santos

Repurposing of approved drugs allows strong savings in time and investment. Rimantadine is an FDA-approved drug for prevention and treatment of influenza A infection. Patent US2021330605 describes the use of rimantadine, an adamantane derivative, for the treatment of melanoma, breast cancer and head and neck squamous cell carcinoma. Rimantadine inhibited proliferation of cell lines of melanoma, breast cancer, and head and neck squamous cell carcinoma, increased the survival of mice injected with cancer cell lines and restores the expression of MHC class I. Rimantadine has the potential to be used successfully in the treatment of head and neck squamous cell carcinoma.

重新利用已批准的药物可以大大节省时间和投资。金刚乙胺是fda批准的预防和治疗甲型流感感染的药物。专利US2021330605描述了金刚烷衍生物金刚乙胺用于治疗黑色素瘤、乳腺癌和头颈部鳞状细胞癌的用途。金刚乙胺抑制黑色素瘤、乳腺癌和头颈部鳞状细胞癌细胞系的增殖,增加注射癌细胞的小鼠的存活率,恢复MHC i类的表达。金刚乙胺有可能成功用于头颈部鳞状细胞癌的治疗。
{"title":"Drug repurposing of rimantadine for treatment of cancer.","authors":"Nemesio Villa-Ruano, Vianey Marin-Cevada, Gabriela Sanchez-Esgua, Luis Villafaña-Diaz, Martin Perez-Santos","doi":"10.4155/ppa-2023-0019","DOIUrl":"10.4155/ppa-2023-0019","url":null,"abstract":"<p><p>Repurposing of approved drugs allows strong savings in time and investment. Rimantadine is an FDA-approved drug for prevention and treatment of influenza A infection. Patent US2021330605 describes the use of rimantadine, an adamantane derivative, for the treatment of melanoma, breast cancer and head and neck squamous cell carcinoma. Rimantadine inhibited proliferation of cell lines of melanoma, breast cancer, and head and neck squamous cell carcinoma, increased the survival of mice injected with cancer cell lines and restores the expression of MHC class I. Rimantadine has the potential to be used successfully in the treatment of head and neck squamous cell carcinoma.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138047731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Pharmaceutical patent analyst
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1